October 24, 2011
MSD and Mylan Seiyaku announced on October 21 that they terminated on the same day their contract to copromote the HMG–CoA reductase inhibitor Lipovas (simvastatin), and the angiotensin converting enzyme inhibitor Renivase (enalapril), both of which MSD manufactures and markets...read more